EPA:ALTHX - Euronext Paris - Matif - FR0013286259 - Common Stock - Currency: EUR
EPA:ALTHX (8/1/2025, 7:00:00 PM)
2.7
+0.66 (+32.35%)
The current stock price of ALTHX.PA is 2.7 EUR. In the past month the price increased by 128.81%. In the past year, price increased by 297.06%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 55.13 | 630.63B | ||
LLY.DE | ELI LILLY & CO | 54.28 | 620.96B | ||
ZEG.DE | ASTRAZENECA PLC | 16.45 | 394.69B | ||
1JNJ.MI | JOHNSON & JOHNSON | 16.59 | 350.32B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.37 | 345.84B | ||
RHO.DE | ROCHE HOLDING AG-BR | 13.53 | 231.28B | ||
SAN.PA | SANOFI | 11.9 | 195.95B | ||
1SAN.MI | SANOFI | 11.89 | 195.73B | ||
SNW.DE | SANOFI | 11.85 | 195.09B | ||
NOT.DE | NOVARTIS AG-REG | 12.93 | 191.67B | ||
NOV.DE | NOVO NORDISK A/S-B | 13.22 | 185.07B | ||
6MK.DE | MERCK & CO. INC. | 10.09 | 171.00B |
Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 12 full-time employees. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
THERANEXUS SADIR
60, Avenue Rockefeller - Pepiniere Laennec
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 12
Phone: 33188897031
The current stock price of ALTHX.PA is 2.7 EUR. The price increased by 32.35% in the last trading session.
The exchange symbol of THERANEXUS SADIR is ALTHX and it is listed on the Euronext Paris - Matif exchange.
ALTHX.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALTHX.PA and the average price target is 5 EUR. This implies a price increase of 85.11% is expected in the next year compared to the current price of 2.7. Check the THERANEXUS SADIR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
THERANEXUS SADIR (ALTHX.PA) has a market capitalization of 20.95M EUR. This makes ALTHX.PA a Nano Cap stock.
THERANEXUS SADIR (ALTHX.PA) currently has 12 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALTHX.PA does not pay a dividend.
THERANEXUS SADIR (ALTHX.PA) will report earnings on 2025-09-25.
THERANEXUS SADIR (ALTHX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
ChartMill assigns a technical rating of 9 / 10 to ALTHX.PA. When comparing the yearly performance of all stocks, ALTHX.PA is one of the better performing stocks in the market, outperforming 99.56% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to ALTHX.PA. Both the profitability and financial health of ALTHX.PA have multiple concerns.
Over the last trailing twelve months ALTHX.PA reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 68.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -72.26% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to ALTHX.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.